Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Small bowel adenocarcinoma: results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.

Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, Vernerey D, Afchain P; NADEGE Investigators.

Int J Cancer. 2020 Jan 7. doi: 10.1002/ijc.32860. [Epub ahead of print]

PMID:
31912484
2.

Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis.

Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, Bourlière M.

Liver Cancer. 2019 Nov;8(6):457-467. doi: 10.1159/000497161. Epub 2019 Mar 27.

3.

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.

Reichling C, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, Becheur H, Fein F, Cojocarasu O, Kaminsky MC, Lagasse JP, Luet D, Nguyen S, Etienne PL, Gasmi M, Vanoli A, Perrier H, Puig PL, Emile JF, Lepage C, Ghiringhelli F.

Gut. 2019 Nov 28. pii: gutjnl-2019-319292. doi: 10.1136/gutjnl-2019-319292. [Epub ahead of print]

4.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
5.

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.

Adhoute X, Pénaranda G, Raoul JL, Pietri O, Bronowicki JP, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1414-1423. doi: 10.1097/MEG.0000000000001420.

PMID:
31045613
6.

Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.

Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M, Bayle O, Beaurain P, Monnet O, Bourlière M.

Eur J Gastroenterol Hepatol. 2018 Apr;30(4):368-375. doi: 10.1097/MEG.0000000000001082.

PMID:
29384796
7.

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.

Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M.

World J Gastroenterol. 2017 Apr 14;23(14):2545-2555. doi: 10.3748/wjg.v23.i14.2545.

8.

NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.

Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):706-715. doi: 10.1097/MEG.0000000000000852.

PMID:
28195873
9.

Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.

Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M.

World J Hepatol. 2016 Jun 18;8(17):703-15. doi: 10.4254/wjh.v8.i17.703. Review.

10.

Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.

Adhoute X, Pénaranda G, Raoul JL, Blanc JF, Edeline J, Conroy G, Perrier H, Pol B, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Bronowicki JP, Bourlière M.

Eur J Gastroenterol Hepatol. 2016 Apr;28(4):433-40. doi: 10.1097/MEG.0000000000000558.

PMID:
26695429
11.

Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?

Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M.

World J Hepatol. 2015 Mar 27;7(3):521-31. doi: 10.4254/wjh.v7.i3.521. Review.

12.

Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.

Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M.

J Hepatol. 2015 Apr;62(4):855-62. doi: 10.1016/j.jhep.2014.11.014. Epub 2014 Nov 21.

PMID:
25463541
13.

Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.

Francois E, Smith D, Dahan L, Michel C, Perrier H, Mari V, Seitz JF, Follana P, Evesque L, Chamorey E.

J Chemother. 2012 Aug;24(4):207-11. doi: 10.1179/1973947812Y.0000000021.

PMID:
23040684
14.

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.

Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL.

Ann Oncol. 2012 Nov;23(11):2799-805. doi: 10.1093/annonc/mds135. Epub 2012 Jul 5.

PMID:
22771827
15.

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.

Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E; Groupe Francophone des Myélodysplasies.

Br J Haematol. 2012 Mar;156(5):619-25. doi: 10.1111/j.1365-2141.2011.08979.x. Epub 2011 Dec 23.

PMID:
22211483
16.

Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.

Macdonald D, Brideau C, Chan CC, Falgueyret JP, Frenette R, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Thérien M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. Epub 2008 Feb 2.

PMID:
18276139
17.

Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.

Gallant M, Chauret N, Claveau D, Day S, Deschênes D, Dubé D, Huang Z, Lacombe P, Laliberté F, Lévesque JF, Liu S, Macdonald D, Mancini J, Masson P, Mastracchio A, Nicholson D, Nicoll-Griffith DA, Perrier H, Salem M, Styhler A, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1407-12. doi: 10.1016/j.bmcl.2008.01.004. Epub 2008 Jan 8.

PMID:
18207397
18.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.

Delord JP, Bennouna J, Artru P, Perrier H, Husseini F, Desseigne F, François E, Faroux R, Smith D, Piedbois P, Naman H, Douillard JY, Bugat R.

Br J Cancer. 2007 Aug 6;97(3):297-301. Epub 2007 Jul 17.

19.

[Sarcoidosis following pegylated interferon therapy: two cases].

Benali S, Boustière C, Castellani P, Cesari C, Jullien M, Lecomte L, Lebars O, Lambot G, Loyer R, Masseboeuf A, Perrier H, Oules V, Bourlière M.

Gastroenterol Clin Biol. 2006 Apr;30(4):615-9. Review. French.

20.

Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560.

Bateman KP, Trimble L, Chauret N, Silva J, Day S, Macdonald D, Dube D, Gallant M, Mastracchio A, Perrier H, Girard Y, Nicoll-Griffith D.

J Mass Spectrom. 2006 Jun;41(6):771-80.

PMID:
16705670
21.

Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.

Lacombe P, Deschênes D, Dubé D, Dubé L, Gallant M, Macdonald D, Mastracchio A, Perrier H, Charleson S, Huang Z, Laliberté F, Liu S, Mancini JA, Masson P, Salem M, Styhler A, Girard Y.

Bioorg Med Chem Lett. 2006 May 15;16(10):2608-12. Epub 2006 Mar 3.

PMID:
16516471
22.

'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.

Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar M, Bordenave S, Seitz JF, Cvitkovic F, Dorval E, Malek K, Tonelli D, Douillard JY.

Br J Cancer. 2006 Jan 16;94(1):69-73.

23.

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Macdonald D, Mastracchio A, Perrier H, Dubé D, Gallant M, Lacombe P, Deschênes D, Roy B, Scheigetz J, Bateman K, Li C, Trimble LA, Day S, Chauret N, Nicoll-Griffith DA, Silva JM, Huang Z, Laliberté F, Liu S, Ethier D, Pon D, Muise E, Boulet L, Chan CC, Styhler A, Charleson S, Mancini J, Masson P, Claveau D, Nicholson D, Turner M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. Epub 2005 Sep 15.

PMID:
16168647
24.

A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.

François E, Hebbar M, Bennouna J, Mayeur D, Perrier H, Dorval E, Martin C, Bourgeois H, Barthélemy P, Douillard JY.

Oncology. 2005;68(4-6):299-305. Epub 2005 Jul 12.

PMID:
16020956
25.

Autoantibodies directed against ribosomal proteins in systemic lupus erythematosus and rheumatoid arthritis: a comparative study.

Desbos A, Gonzalo P, Monier JC, Tebib J, Reboud JP, Perrier H, Bienvenu J, Fabien N.

Autoimmunity. 2002 Nov;35(7):427-34.

PMID:
12685870
26.

Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users.

Bourlière M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, Benali S, Boustière C, Perrier H, Jullien M, Lambot G, Loyer R, LeBars O, Daniel R, Khiri H, Halfon P.

J Viral Hepat. 2002 Jan;9(1):62-70.

PMID:
11851904
27.

[Medical aspects of the life of Richard Wagner].

Bouteldja P, Perrier H, Faure M.

Rev Prat. 1998 Apr 1;48(7):705-8. French. No abstract available.

PMID:
11767363
28.

Liquid-Phase Synthesis with Solid-Phase Workup: Application to Multistep and Combinatorial Syntheses.

Perrier H, Labelle M.

J Org Chem. 1999 Mar 19;64(6):2110-2113. No abstract available.

PMID:
11674308
29.

Onset of coeliac disease and interferon treatment.

Bourlière M, Oulés V, Perrier H, Mengotti C.

Lancet. 2001 Mar 10;357(9258):803-4. No abstract available.

PMID:
11253998
30.

Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization.

Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ.

Drug Metab Dispos. 2001 Mar;29(3):232-41.

PMID:
11181489
31.

Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).

Macdonald D, Perrier H, Liu S, Laliberté F, Rasori R, Robichaud A, Masson P, Huang Z.

J Med Chem. 2000 Oct 19;43(21):3820-3. No abstract available.

PMID:
11052785
32.

[Use of echocardiography in the diagnosis of carcinoid tumors. Report of 4 cases].

Aviérinos JF, Habib G, Garcia M, Lefèvre J, Médail C, Dufaut F, Philip E, Ambrosi P, Perrier H, Luccioni R.

Arch Mal Coeur Vaiss. 2000 Mar;93(3):277-83. French.

PMID:
11004974
33.

Covert transmission of hepatitis C virus during bloody fisticuffs.

Bourlière M, Halfon P, Quentin Y, David P, Mengotti C, Portal I, Khiri H, Benali S, Perrier H, Boustière C, Jullien M, Lambot G.

Gastroenterology. 2000 Aug;119(2):507-11.

PMID:
10930386
34.

Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins.

Fabien N, Moreira A, Lavergne JP, Desbos A, Surgey P, Alves de Olivera C, Gonzalo P, Venot A, Bienvenu J, Perrier H, Reboud JP, Monier JC.

J Autoimmun. 1999 Aug;13(1):103-10.

PMID:
10441174
35.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

PMID:
10411562
36.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8.

PMID:
10406640
37.

Substituted furans as inhibitors of the PDE4 enzyme.

Perrier H, Bayly C, Laliberté F, Huang Z, Rasori R, Robichaud A, Girard Y, Macdonald D.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6.

PMID:
10091677
38.

[Hemorrhagic rectocolitis and autoimmune hemolytic anemia].

Heyries L, Bernard JP, Perrier H, Daniel R, Valantin V, Sahel J.

Gastroenterol Clin Biol. 1998 Aug-Sep;22(8-9):741-2. French. No abstract available.

39.

5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.

Seitz JF, Perrier H, Giovannini M, Capodano G, Bernardini D, Bardou VJ.

J Chemother. 1998 Jun;10(3):258-65.

PMID:
9669654
40.

[Induction treatment of locally advanced operable cancers of the esophagus. Prognostic significance of the histologic response].

Thomas P, Doddoli C, Giacoia A, Garbe L, Perrier H, Giovannini M, Seitz JF, Hannoun-Levi JM, Giudicelli R, Fuentes P.

Ann Chir. 1997;51(3):222-31. French.

PMID:
9297883
41.

[Recurrence after surgical treatment of epidermoid cancers of the esophagus. Therapeutic approach in 19 patients].

Seitz JF, Renou C, Perrier H, Thomas P, Hannoun-Levy JM, Giovannini M, Bardou VJ, Hardwigsen J, Guidicelli R, Fuentes P.

Gastroenterol Clin Biol. 1997;21(4):287-92. French.

42.

Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer.

Giovannini M, Seitz JF, Thomas P, Hannoun-Levy JM, Perrier H, Resbeut M, Delpero JR, Fuentes P.

Endoscopy. 1997 Jan;29(1):4-9.

PMID:
9083729
43.

[Immunotherapy of colorectal cancers].

Bécouarn Y, Seitz JF, Perrier H, Rouhier ML, Giovannini M, Brunet R.

Gastroenterol Clin Biol. 1996 Feb;20(1):20-32. Review. French. No abstract available.

PMID:
8734308
44.

[Surgical treatment of esophageal cancer in patients over 70 years of age].

Thomas P, Hardwigsen H, Lienne P, Giudicelli R, Perrier H, Giovannini M, Seitz JF, Reboud E, Fuentes P.

Chirurgie. 1996;121(2):101-7. Review. French.

PMID:
8763113
45.

[Use of 5-fluorouracil in digestive cancer].

Setiz JF, Perrier H, Giovannini M, Thill L.

Gastroenterol Clin Biol. 1996;20(5 Pt 2):B80-88. Review. French. No abstract available.

PMID:
8761126
46.

Continuous, vesicle-based fluorimetric assays of 14- and 85-kDa phospholipases A2.

Bayburt T, Yu BZ, Street I, Ghomashchi F, Laliberté F, Perrier H, Wang Z, Homan R, Jain MK, Gelb MH.

Anal Biochem. 1995 Nov 20;232(1):7-23.

PMID:
8600835
47.

[Uterine metastasis revealing gastric adenocarcinoma].

Mambrini P, Giovanini M, Seitz JF, Perrier H, Allemand I, Rabia I, Monges G, Lebreuil G.

Gastroenterol Clin Biol. 1995 Aug-Sep;19(8-9):725-8. French.

PMID:
8522124
48.

Purification of baculovirus-overexpressed cytosolic phospholipase A2 using a single-step affinity column chromatography.

Abdullah KM, Leger S, Perrier H, Cromlish WA, Kennedy B, Gresser M.

Protein Expr Purif. 1995 Jun;6(3):291-7.

PMID:
7663164
49.
50.

[Cancer of the esophagus and cardia:therapeutic strategy in inoperable patients].

Seitz JF, Perrier H, Giovannini M.

Ann Gastroenterol Hepatol (Paris). 1995 Mar-Apr;31(2):60-6, 69. Review. French. No abstract available.

PMID:
7618844

Supplemental Content

Loading ...
Support Center